Moleculin Biotech Inc (MBRX): Moleculin Shares Gain Pre-Bell After Co...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	55
Posts	13535
Boards Moderated	0
Alias Born	10/12/2006

king oil

Re: None

Thursday, 12/21/2017 2:15:36 PM

Thursday, December 21, 2017 2:15:36 PM

Moleculin Shares Gain Pre-Bell After Co Gets Polish Approval for Leukemia Clinical Trial

09:07 AM EST, 12/21/2017 (MT Newswires) -- Moleculin Biotech (MBRX) jumped in premarket trading Thursday after the clinical stage pharmaceutical company said the Ethics Committee in Poland has approved the company's phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Shares rose more than 7%.

"We have been highly focused on accelerating our clinical development of Annamycin," Moleculin CEO Walter Klemp said in a statement. "The protocol approved in Poland allows us to move more aggressively in identifying the optimum dosing for AML patients, which in turn should allow us to move into phase II data generation more expeditiously."

A site initiation visit for the first treatment site was completed this week and treatment of patients in Poland is now subject only to confirmation by the Polish National Office that all necessary forms have been properly filed. The company said it expects the first patient to be enrolled in Q1.